ENDRA Life Sciences Inc. (NDRA) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
Analysts estimate Earnings Per Share (EPS) of $-47.46 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-56.94 vs est $-47.46 (missed -20%). 2025: actual $-8.93 vs est $-6.59 (missed -35.5%). Analyst accuracy: 79%.
NDRA Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to ENDRA Life Sciences Inc. in the past 3 months
EPS Estimates — NDRA
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$56.94
vs Est –$47.46
▼ 16.6% off
2025
Actual –$8.93
vs Est –$6.59
▼ 26.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NDRA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
